A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

NCT04305197 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: ICP-022
DRUG: ICP-022
DRUG: ICP-022
DRUG: Placebos

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.